Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | DHCR24 | Q15392 | 6/20 | 0.54 |
| ▸ | CDC25A | P30304 | 6/20 | 0.49 |
| ▸ | CDC25B | P30305 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29656314 | 1.00 | MEN1 (0.74) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL6398718 | 0.90 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL27774330 | 0.89 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL1957036 | 0.89 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL30875104 | 0.89 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL28225571 | 0.87 | ALDH1A1 (0.60) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL30266882 | 0.87 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL30685282 | 0.87 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL30778467 | 0.87 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL7247289 | 0.86 | USP2 (0.79) | MEN1KMT2AALDH1A1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4683905-A1 | IONIZABLE ANIONIC LIPIDS | Nanovation Therapeutics Inc. (CA) | 2026-01-28 | — | — | EP | disclosed |
| EP-4676446-A1 | NOVEL LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025213271-A1 | METHOD OF DELIVERING NUCLEIC ACID TO MACROPHAGES AND/OR MONOCYTES AND COMPOSITIONS FOR USE THEREOF | NANOVATION THERAPEUTICS INC. (CA) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025213270-A1 | METHOD OF DELIVERING NUCLEIC ACID TO T CELLS AND COMPOSITIONS FOR USE THEREOF | NANOVATION THERAPEUTICS INC. (CA) | 2025-10-16 | — | — | WO | disclosed |
| US-20250161425-A1 | SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES | SANOFI PASTEUR INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2024192528-A1 | IONIZABLE ANIONIC LIPIDS | NANOVATION THERAPEUTICS INC. (CA) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024184500-A1 | NOVEL LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2024-09-12 | — | — | WO | disclosed |
| WO-2022192511-A1 | NANOTHERAPEUTICS FOR TREATMENT OF SARS-COV-2 | OREGON STATE UNIVERSITY (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-4037718-A1 | LIPOSOMES COMPRISING ANTI-LOX ANTIBODY | Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. (IT) | 2022-08-10 | — | — | EP | disclosed |
| US-20220228190-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161425-A1 | SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES | PHAX, RNGTT, SRPRA | MEN1 3037/4885KMT2A 4763/4885ALDH1A1 4858/4885 |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | MEN1 4321/4885KMT2A 4140/4885ALDH1A1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.